Anti-PD1 antibody [NAT105] (Ab52587)
CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1
详细信息
背景信息
Anti-PD1 antibody [NAT105] (ab52587) is a mouse recombinant monoclonal antibody and is validated for use in Flow Cyt, ICC/IF, IHC-Fr, IHC-P and WB. Anti-PD1 antibody [NAT105] (ab52587) was first used in a scientific publication in 2007 and has been cited over 282 times in peer reviewed journals. It's performance in IHC in human samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-PD1 antibody [NAT105] (ab52587) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-PD1 antibody [NAT105] (ab52587) has 8 independent reviews from customers. Anti-PD1 antibody [NAT105] (ab52587) specifically detects PD1 (UniProt ID: Q15116; Molecular weight: 29kDa) and is sold in a convenient trial size to enable initial testing (20 µg) and larger sizes for subsequent scaling up experiments (100 ug and 1 mg). Conjugation-ready, carrier free format available for antibody clone NAT105 - ab201811. Antibody clone NAT105 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, Alexa Fluor ® 647, PE, Alexa Fluor ® 647, Alexa Fluor ® 555 ( ab220300, ab220301, ab220302, ab279695, ab280864 ). PD-1 is an immune checkpoint receptor that, when engaged by its ligands PD-L1 or PD-L2, inhibits T-cell activity, allowing tumors to evade immune detection. Blocking the PD-1 pathway with immune checkpoint inhibitors reactivates T-cells, enhancing the immune system's ability to target and destroy cancer cells. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.
文献引用 (219)
Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan
肿瘤免疫微环境对接受阿维鲁单抗、西妥昔单抗和伊立替康治疗的微卫星稳定型转移性结直肠癌的影响
IRF4 Promotes Immune Evasion and Shapes the Tumor Microenvironment in Follicular Lymphoma
IRF4促进滤泡性淋巴瘤的免疫逃逸并塑造肿瘤微环境
MIAT promotes tumor-infiltrating CD8(+) T-cell exhaustion and malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway.
MIAT 通过激活 JAK3/STAT3 通路促进肿瘤浸润 CD8(+) T 细胞耗竭和肾细胞癌的恶性进展
The endoplasmic reticulum degradation-enhancing α-mannosidase-like protein 3 attenuates the unfolded protein response and has pro-survival and pro-viral roles in hepatoma cells and hepatocellular carcinoma patients
内质网降解增强型 α-甘露糖苷酶样蛋白 3 可减弱未折叠蛋白反应,并在肝癌细胞和肝细胞癌患者中发挥促存活和促病毒作用
Immune profiling of premalignant lesions in patients with Peutz-Jeghers syndrome.
对患有Peutz-Jeghers综合征的患者进行癌前病变的免疫分析
Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma.
成熟的三级淋巴结构与 HPV 状态和基于抗 PD-1 的头颈部鳞状细胞癌化疗免疫治疗反应相关
Prognostic and immunological implications of cathepsin Z overexpression in prostate cancer.
组织蛋白酶 Z 过表达在前列腺癌中的预后和免疫学意义
Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes.
针对儿童肉瘤的 Mucin 16 靶向治疗:Ubamatamab 在上皮样肉瘤中的疗效病例证据及其对其他肉瘤亚型的意义
Insulin Modulates NK Cell Activity in Liver Fibrosis MASH Patients via the STING Pathway.
胰岛素通过 STING 通路调节肝纤维化 MASH 患者的 NK 细胞活性
WTAP Accelerates Exhaustion of CD8(+) T Cells and Progression of Hepatocellular Carcinoma by Promoting m6A Modification and Translation of PD1 mRNA.
WTAP 通过促进 PD1 mRNA 的 m6A 修饰和翻译,加速 CD8(+) T 细胞的耗竭和肝细胞癌的进展
- 1
- 2
- 3
- 4
- 5
- 6
- 22